IriSys to be Represented at CPhI Japan by Chairman, CEO & Founder Gerald Yakatan, Ph.D.

– Dr. Yakatan will hold meetings to discuss IriSys’ customized services for international clients –


San Diego, April 12, 2017 – IriSys, LLC, a San Diego-based provider of contract pharmaceutical product development and manufacturing services, today announced that Gerald Yakatan, Ph.D., Chairman, CEO and founder of IriSys, will be attending and holding meetings at CPhI Japan in Tokyo on April 19-21, 2017.  CPhI Japan is the country’s most comprehensive pharma event and has been the central platform for international businesses for more than 10 years.

“CPhI Japan is an excellent setting to discuss IriSys’ customized services that support the special needs of our international clients,” said Gerald Yakatan, Ph.D., Chairman, CEO and founder of the Company.  “IriSys has helped numerous foreign companies take their new drug products through the entire FDA regulatory process. In addition to working with Japanese companies, we have helped clients in Australia, China, Korea and Russia.”

IriSys helps international companies by providing strategy and guidance throughout the U.S. FDA approval process.  In addition, IriSys can educate their clients’ personnel about FDA regulatory requirements and provide translations of regulatory documents.  Meetings take place at the client’s location or in San Diego, California, where IriSys maintains its headquarters, laboratories and state-of-the-art manufacturing facility.

As Asia’s leading pharma industry and one of the world’s largest markets, Japan is an excellent location to discuss the latest technologies and innovative products. Changes in the market environment, together with an aging population, result in a great drug demand within Japan, especially in the generic and biotechnology sectors.  According to the CPhI Japan organizers, the Japanese market is expected to be valued at US $115 billion in 2024.

CPhI Japan 2017, which is focused on pharmaceutical ingredients, is expected to have more than 19,000 attendees.  Decision-makers representing leading companies from all over the world will participate in a wide range of seminars that include speakers from the government, industry associations and other key organizations.

About IriSys, LLC

IriSys was founded in 1996 to provide contract pharmaceutical product development and manufacturing services, specializing in formulation development, cGMP manufacturing of clinical trial materials and commercial pharmaceutical products, and strategic consulting related to the drug development process. IriSys’ custom approach to drug development is supported by the Company’s scientific and regulatory experience in moving more than 100 drug products from discovery to clinical development and commercialization.

About CPhI Japan (http://ubm.cphi.com/jp17-mpba/)

CPhI Japan 2017 is Japan’s largest and leading pharmaceutical exhibition, which brings together more than 19,000 pharma industry professionals from 100+ countries. Network, source new suppliers, develop new and existing relationships and do business in pharma – all in one location. CPhI Japan and co-located events ICSE, P-MEC, BioPh and InnoPack represent the entire pharmaceutical supply chain and its key players. Exhibitors are divided into different zones on the show floor, helping you to access quality leads that are relevant to your business.

IriSys Contacts

Louis Scotti
Vice President Business Development
+1-858-281-7943
lscotti@irisys.com

Gwen Rosenberg
Rosenberg Business Communications
+1-858-525-5484
gwen@rosenbergbc.com